☆ 4.6 Editorial Material

Triple-negative breast cancer: Heterogeneity, tumor microenvironment and targeted therapy

FRONTIERS IN ONCOLOGY (2022)

Related references

Note: Only part of the references are listed.

Review Oncology

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier

Somayeh Vafaei et al.

Summary: Immune checkpoint inhibitors have become a promising therapeutic strategy with durable anti-tumor effects, but resistance to these inhibitors and treatment-related toxicities pose challenges to their clinical utility. Combination therapy with immune checkpoint inhibitors and other treatments can effectively overcome tumor resistance.

CANCER CELL INTERNATIONAL (2022)

Add to Collection

Article Cell Biology

A Novel Platelet-Related Gene Signature for Predicting the Prognosis of Triple-Negative Breast Cancer

Jindong Xie et al.

Summary: Platelet-related genes were identified and a seven-gene signature was constructed to classify TNBC patients into low- or high-risk groups. Patients in the high-risk group had lower survival rates, and the risk score, combined with clinical features, was confirmed as an independent factor for predicting overall survival time. Functional enrichment analyses revealed the involvement of vital biological processes and cancer-related pathways in TNBC prognosis.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

Add to Collection

Review Pharmacology & Pharmacy

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers

Linjie Luo et al.

Summary: This review examines completed or ongoing clinical trials of PARPi mono- and combination therapies. The review focuses on PARPi monotherapy in HER2 negative breast (HR+ and TNBC subtypes) and ovarian cancer. The authors propose potential strategies to overcome PARPi resistance and discuss key questions and future directions.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)

Add to Collection

Editorial Material Oncology

Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?

Marek Z. Wojtukiewicz et al.

CANCER AND METASTASIS REVIEWS (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan

Julia E. McGuinness et al.

Summary: SG, LV, and T-DXd have shown potential to significantly improve clinical outcomes in pretreated mTNBC patients, with notable response rates in phase I/II and phase III clinical trials. Investigation into their use in combination with other agents is ongoing, and their application in early-stage TNBCs is being explored. ADCs are anticipated to redefine treatment approaches in TNBC.

EXPERT OPINION ON BIOLOGICAL THERAPY (2021)

Add to Collection

Article Pathology

A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases

Richard S. P. Huang et al.

Summary: The study examined PD-L1 expression in a wide variety of tumor types and its relationship with MSI, TMB, and CD274 gene amplification. It found a high correlation between PD-L1 expression and these biomarkers, as well as identified four unique disease subsets based on PD-L1 and TMB status. The analysis of over 48,000 cases provides valuable insights for potential response to immunotherapy.

MODERN PATHOLOGY (2021)

Add to Collection

Article Oncology

Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?

Xupeng Bai et al.

Summary: TNBC shows higher response rate to systemic therapy but poorer tumor differentiation, with higher tendency to metastasis and recurrence. Relapsed and metastatic TNBCs progress more rapidly, demonstrating strong resistance to chemotherapy and radiotherapy.

CANCER LETTERS (2021)

Add to Collection

Article Oncology

Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients

Jieqiong Liu et al.

Summary: In this study, potential biomarkers for combinational anti-angiogenesis and immunotherapy in advanced TNBC patients were analyzed. Findings show that higher baseline TILs or a greater increase of tumor-infiltrating CD8(+) T cells during therapy, lower baseline plasma HGF/IL-8, a decrease of plasma IL-8, an increase of plasma TIM-3/CD152 during therapy, higher baseline CD4(+) T cells or B cells proportion in blood could be indicators of treatment response for this patient population.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Add to Collection

Review Biochemistry & Molecular Biology

TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy

Desh Deepak Singh et al.

Summary: Triple-negative breast cancer (TNBC) is a heterogeneous cancer with high metastasis rate and poor prognosis, lacking effective therapeutic targets. Target-based therapeutic options are limited, and there is a need for more effective treatments. Effective biomarkers distinguishing TNBC from other subtypes are lacking.

BIOMEDICINES (2021)

Add to Collection

Article Oncology

miR-30a/SOX4 Double Negative Feedback Loop is modulated by Disulfiram and regulates EMT and Stem Cell-like properties in Breast Cancer

Zijian Liu et al.

Summary: miR-30a inhibits EMT and CSC phenotypes in breast cancer cells by targeting SOX4 and forming a double-negative feedback loop. Knockdown of SOX4 suppresses EMT and CSC phenotypes through the TGF-beta/SMAD pathway, consistent with the effects of miR-30a overexpression. High expression of miR-30a is associated with a good prognosis in breast cancer patients.

JOURNAL OF CANCER (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Salinomycin Derivatives Kill Breast Cancer Stem Cells by Lysosomal Iron Targeting

Antoine Versini et al.

CHEMISTRY-A EUROPEAN JOURNAL (2020)

Add to Collection

Editorial Material Oncology

Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer

Peter Savas et al.

CANCER CELL (2020)

Add to Collection

Review Oncology

Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer

Manzoor A. Mir et al.

CURRENT CANCER DRUG TARGETS (2020)

Add to Collection

Review Oncology

Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment

Ana C. Garrido-Castro et al.

CANCER DISCOVERY (2019)

Add to Collection

Article Oncology

Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer

Heather A. Parsons et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Medicine, General & Internal

Molecular alterations in triple-negative breast cancer-the road to new treatment strategies

Carsten Denkert et al.

LANCET (2017)

Add to Collection

Article Cell Biology

Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation

Peiguo Shi et al.

CELL DISCOVERY (2017)

Add to Collection

Article Medicine, Research & Experimental

Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression

Rong Liu et al.

THERANOSTICS (2016)

Add to Collection

© Peeref 2019-2024. All rights reserved.